Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alcon Could Re-File Patanase Nasal Spray NDA By End Of 2007

This article was originally published in The Pink Sheet Daily

Executive Summary

Olopatadine reformulation will require additional preclinical testing, firm says.

You may also be interested in...



Alcon Enters Nasal Market With Approval Of Seasonal Allergic Rhinitis Spray

Swiss eye care company wins FDA approval of Patanase after withdrawal and resubmission of NDA.

Alcon Enters Nasal Market With Approval Of Seasonal Allergic Rhinitis Spray

Swiss eye care company wins FDA approval of Patanase after withdrawal and resubmission of NDA.

FDA Raises Concerns About Patanase Inactive Ingredient

Alcon is testing a modified formulation of the olopatadine nasal spray, which is awaiting approval for treatment of seasonal allergic rhinitis.

Related Content

Topics

UsernamePublicRestriction

Register

PS063746

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel